NAC was originally restricted to patients with inflammatory or locally advanced BC, but is now the standard care for aggressive early-stage breast cancers, i.e., triple-negative (TNBC) and HER2-positive BCs8,9. The gene discussed is ERBB2; the disease is breast cancer.